Literature DB >> 30919036

The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial.

Azadeh Akbari Sene1, Azam Tabatabaie1, Hossein Nikniaz2, Ahad Alizadeh3, Kourosh Sheibani4, Mona Mortezapour Alisaraie1, Maryam Tabatabaie1, Mahnaz Ashrafi1,5, Fatemehsadat Amjadi6,7.   

Abstract

PURPOSE: The aim of the present study was to evaluate the effect of myo-Inositol administration on oocyte quality, fertilization rate and embryo quality in patients with PCOS during assisted reproductive technology (ART) cycles.
METHODS: Fifty infertile PCOS patients were randomly designated in two groups. In the study group, patients received daily doses of 4 g myo-Inositol combined with 400 mg folic acid and in the control group patients received only 400 mg folic acid from 1 month before starting the antagonist cycle until the day of ovum pick up. Oocyte and embryo qualities were assessed according to European Society of Human Reproduction and Embryology (ESHRE) guidelines. The gene expression of PGK1, RGS2 and CDC42 as a factor of oocyte quality in granulosa cells was analyzed using real-time RT-PCR. Levels of total antioxidant capacity (TAC) and reactive oxygen species (ROS) were evaluated by chemiluminescence assay in follicular fluid.
RESULTS: The percentage of metaphase II oocyte, fertilization rate and embryo quality significantly improved in the study group (p < 0.05), but the number of retrieved oocytes and follicle count were not statistically different between groups. Furthermore, the gene expression of PGK1, RGS2 and CDC42 was significantly higher in the study group (p < 0.05) but no differences were found between two groups in terms of TAC and ROS levels.
CONCLUSIONS: The present study findings suggest that myo-Inositol alters the gene expression in granulosa cells and improves oocyte and embryo quality among PCOS patients undergoing ART.

Entities:  

Keywords:  Assisted reproductive technology; Fertilization; Oocyte; Polycystic ovary syndrome; myo-Inositol

Mesh:

Substances:

Year:  2019        PMID: 30919036     DOI: 10.1007/s00404-019-05111-1

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  3 in total

1.  The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Elfatih A Hasabo; Mohamed Ibrahim Abdelraoof; Mohamed Alshandidy; Muhammad Eid; Esraa Menshawy; Oumaima Outani; Ahmed Menshawy
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

Review 2.  Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies.

Authors:  Philippe Merviel; Pandora James; Sarah Bouée; Mathilde Le Guillou; Camille Rince; Charlotte Nachtergaele; Véronique Kerlan
Journal:  Reprod Health       Date:  2021-01-19       Impact factor: 3.223

Review 3.  Advances in the study of CDC42 in the female reproductive system.

Authors:  Qiaojuan Mei; Huiying Li; Yu Liu; Xiaofei Wang; Wenpei Xiang
Journal:  J Cell Mol Med       Date:  2021-12-03       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.